Study of Bretuximab Vedotin Compared to Physician's Choice in Patients With CD30-Positive Cutaneous T-Cell Lymphoma To determine ORR, lasting at least 4 months, with brentuximab vedotin in patients with CD30+ MF or pcALCL compared to that achieved with therapy in the control arm

• Country None
• organs None
• Specialty None

A trial to evaluate MLN0264 for the treatment of tumors of the stomach or the junction between the esophagus and the stomach and which have a protein called Guanylyl Cyclase C (GCC) present, in patients that have been treated previously but who have relapsed or in whom the cancer has spread To evaluate the overall response rate of patients with recurrent or metastatic GCC-positive adenocarcinoma of the stomach or gastroesophageal junction treated with MLN0264

• Country None
• organs None
• Specialty None

MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy. MLN0128 en combinación con Fulvestrant en mujeres con cáncer de mama avanzado o metastásico después de un tratamiento con inhibidores de la aromatasa - To compare the PFS of patients treated with the combination of fulvestrant+daily MLN0128 versus patients treated with single-agent fulvestrant. - To compare the PFS of patients treated with the comb...

• Country None
• organs None
• Specialty None

A Phase 2 clinical trial of orally taken investigational product (called MLN9708) in adult patients with returning and/or not responding Follicular Lymphoma Ensayo clínico fase 2 del producto en investigación (llamado MLN9708) que se administra por vía oral en pacientes adultos con linfoma folicular que recae y no responde The primary objective is to evaluate the anti-tumor activity of oral ixazomib as measured by ORR in adult patients with relapsed and/or refractory FL. El objetivo principal es evaluar la activid...

• Country None
• organs None
• Specialty None

A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome To estimate antitumor activity of MLN8237 as measured by response rate in patients with AML and high-grade MDS

• Country None
• organs None
• Specialty None

Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment To determine whether the addition of oral MLN9708 to lenalidomide and dexamethasone improves progression-free survival (PFS) in patients with newly-diagnosed multiple myeloma (NDMM)

• Country None
• organs None
• Specialty None

To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment To determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression-free survival (PFS) in patients with relapsed and/or refractory mult...

• Country None
• organs None
• Specialty None

Phase 4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma To assess the antitumor efficacy of single-agent brentuximab vedotin (1.8 mg/kg administered intravenously every 3 weeks) as measured by the overall objective response rate (ORR) in patients with rela...

• Country None
• organs None
• Specialty None

A trial to evaluate MLN0264 for the treatment of pancreatic tumors which have a protein called Guanylyl Cyclase C (GCC) present, in patients that have been treated previously and in whom the cancer is advanced or has spread To evaluate the overall response rate (ORR) of patients with advanced or metastatic GCC-positive adenocarcinoma of the pancreas treated with MLN0264

• Country None
• organs None
• Specialty None

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis Primary Objective for the Induction Phase • To determine the effect of MLN0002 induction treatment on clinical response at 6 weeks Primary Objective for the Maintenance Phase • To determine th...

• Country None
• organs None
• Specialty None